Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 19Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Follicular 10Waldenstrom Macroglobulinemia 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Non-Hodgkin 8Neoplasms 7Lymphoma 7Recurrence 5Lymphoma, B-Cell 5Multiple Myeloma 4Burkitt Lymphoma 4Leukemia, Myeloid, Acute 3Leukemia, Lymphoid 3Leukemia, B-Cell 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Prolymphocytic, B-Cell 2Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Primary Central Nervous System Lymphoma (PCNSL) 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1

Interventions

ibrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Primary Central Nervous System Lymphoma (PCNSL) × ibrutinib × Clear all
NCT07082868 2026-05-06

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
26 enrolled
CNSLymphoid

Primary Central Nervous System Lymphoma (PCNSL)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡